A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1).

Trial Profile

A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 May 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Neurofibromatoses; Plexiform neurofibroma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 10 May 2016 Study phase changed from phase IV to phase II, adverse events added as primary endpoint hence trial focus changed from TU to TU + AR.
    • 10 May 2016 Status changed from completed to discontinued due to poor patients' accrual.
    • 24 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top